MINNEAPOLIS, March 10 /PRNewswire-FirstCall/ -- Uroplasty, Inc. , a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today announced the introduction of a newly designed endoscopic injection needle that can be used in conjunction with the system used to inject Macroplastique(R). Macroplastique is a soft-tissue urethral bulking agent used to treat adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. This permanent, nonresorbable material is injected into the tissues surrounding the urethra to help improve urethral closure to enhance bladder control.
“Durability of Urethral Bulking Injection for Female Stress Urinary Incontinence: 2-Year Results of a Multicenter Study” will appear in the April 2010 print edition (e-published on February 22, 2010) of The Journal of Urology(R). “With the publication of this important clinical study, combined with the introduction of the lower-profile needle, Uroplasty believes that the Macroplastique sales momentum we are already experiencing will continue,” said Uroplasty Chief Executive Officer and President David Kaysen. “The new, smaller diameter endoscopic needle will increase our access to more urologists and urogynecologists who can now use Macroplastique with their current cystoscope. We saw U.S. Macroplastique sales more than double in the last fiscal year and we anticipate continued strong interest with associated sales growth,” concluded Mr. Kaysen.
Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions. Our primary focus is the continued commercialization of our Urgent(R) PC system, which we believe is the only FDA-approved minimally invasive nerve stimulation device designed for office-based treatment of urinary urgency, urinary frequency and urge incontinence - symptoms often associated with overactive bladder. We also offer Macroplastique(R), an injectable bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. Please visit Uroplasty, Inc. at http://uroplasty.com.
Forward-Looking Information
CONTACT: David Kaysen, President and CEO, or Medi Jiwani, Vice President,
CFO, Treasurer, both of Uroplasty, Inc., +1-952-426-6140; or Doug Sherk
(Investors), +1-415-896-6820, or Chris Gale (Media), +1-646-201-5431, both
of EVC Group, for Uroplasty, Inc.
Web site: http://www.uroplasty.com/
